Cargando…
Procalcitonin decrease predicts survival and recovery from dialysis at 28 days in patients with sepsis-induced acute kidney injury receiving continuous renal replacement therapy
Procalcitonin (PCT) is a biomarker for diagnosing infections and guiding antibiotic therapy. In this study, we investigated whether PCT can predict survival and recovery at 28 days in critically ill patients with sepsis-induced acute kidney injury (SIAKI) receiving continuous renal replacement thera...
Autores principales: | Kim, Il Young, Kim, Suji, Ye, Byung Min, Kim, Min Jeong, Kim, Seo Rin, Lee, Dong Won, Lee, Soo Bong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794048/ https://www.ncbi.nlm.nih.gov/pubmed/36574383 http://dx.doi.org/10.1371/journal.pone.0279561 |
Ejemplares similares
-
Effect of fluid overload on survival in patients with sepsis-induced acute kidney injury receiving continuous renal replacement therapy
por: Kim, Il Young, et al.
Publicado: (2023) -
Procalcitonin as a prognostic marker for sepsis based on SEPSIS‐3
por: Jekarl, Dong Wook, et al.
Publicado: (2019) -
Worsening or improving hypoalbuminemia during continuous renal replacement therapy is predictive of patient outcome: a single-center retrospective study
por: Rhee, Harin, et al.
Publicado: (2022) -
Maintenance of the critical care system during the pandemic in non-COVID-19 patients requiring continuous renal replacement therapy: a single center experience
por: Rhee, Harin, et al.
Publicado: (2022) -
The Association of an Early Net Ultrafiltration Rate and 28-Day Mortality in Patients Receiving Continuous Kidney Replacement Therapy
por: Wu, Buyun, et al.
Publicado: (2021)